Skip to main content
SpringerLink
Log in

Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C for Peritoneal Carcinomatosis from Nonappendiceal Colorectal Carcinoma

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: Cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC) are efficacious in patients with disseminated mucinous tumors of the appendix. We reviewed our experience using this approach for nonappendiceal colorectal cancer (NACC).

Methods: We performed a retrospective chart review of a prospective database for patients undergoing CS and IPHC with mitomycin C for peritoneal carcinomatosis from colorectal primary lesions between December 1991 and April 2002.

Results: There were 77 patients, with a median age of 54 years. Peritoneal carcinomatosis was synchronous and metachronous in 27% and 73% patients, respectively. Seventy-five percent of patients (n = 58) had received chemotherapy prior to IPHC. Complete resection of all gross disease was accomplished in 37 patients (48%). The mean carcinoembryonic antigen level decreased from a preoperative value of 31.2 to a postoperative value of 6.9 (P < .0001). Overall survival (OS) at 1, 3, and 5 years was 56%, 25%, and 17%, respectively. With a median follow-up of 15 months, the median OS was 16 months. Perioperative morbidity and mortality were 30% and 12%, respectively. Hematologic toxicity occurred in 15 patients (19%). Cox regression analysis identified poor performance status (P = .018), bowel obstruction (P = .001), malignant ascites (P = .001), and incomplete resection of gross disease (P = .011) as independent predictors of decreased survival. Patients with complete resection of all gross disease had a 5-year OS of 34%, with a median OS of 28 months.

Conclusions: CS and IPHC with mitomycin C can improve outcomes for select patients with peritoneal spread from NACC. One third of patients who undergo complete resection of gross disease have long-term survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pilati P, Rossi CR, Mocellin S, et al. Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol 2001;27:125–134.

    Article  PubMed  CAS  Google Scholar 

  2. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358–363.

    Article  PubMed  CAS  Google Scholar 

  3. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer 1989;63:364–367.

    Article  PubMed  CAS  Google Scholar 

  4. Wong CS, Harwood AR, Cummings BJ, Keane TJ, Thomas GM, Rider WD. Total abdominal irradiation for cancer of the colon. Radiother Oncol 1984;2:209–214.

    Article  PubMed  CAS  Google Scholar 

  5. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985;12:1–6.

    PubMed  CAS  Google Scholar 

  6. Schneebaum S, Arnold MW, Staubus A, Young DC, Dumond D, Martin EW Jr. Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol 1996;3:44–50.

    Article  PubMed  CAS  Google Scholar 

  7. Yonemura Y, Fujimura T, Fushida S, et al. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 1991;15:530–535.

    Article  PubMed  CAS  Google Scholar 

  8. Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998;83:1251–1261.

    Article  PubMed  CAS  Google Scholar 

  9. Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999;6:582–590.

    Article  PubMed  CAS  Google Scholar 

  10. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6:790–796.

    Article  PubMed  CAS  Google Scholar 

  11. Cavaliere F, Di Filippo F, Botti C, et al. Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis. Eur J Surg Oncol 2000;26:486–491.

    Article  PubMed  CAS  Google Scholar 

  12. Beaujard AC, Glehen O, Caillot JL, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000;88:2512–2519.

    Article  PubMed  CAS  Google Scholar 

  13. Watanabe M, Tanaka R, Hondo H, Kuroki M. Effects of antineoplastic agents and hyperthermia on cytotoxicity toward chronically hypoxic glioma cells. Int J Hyperthermia 1992;8:131–138.

    Article  PubMed  CAS  Google Scholar 

  14. Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res 1981;41:1096–1099.

    PubMed  CAS  Google Scholar 

  15. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727–731.

    Article  PubMed  CAS  Google Scholar 

  16. Piso P, Bektas H, Werner U, et al. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol 2001;27:286–290.

    Article  PubMed  CAS  Google Scholar 

  17. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001;88:458–463.

    Article  PubMed  CAS  Google Scholar 

  18. Wirtzfeld DA, Rodriguez-Bigas M, Weber T, Petrelli NJ. Disseminated peritoneal adenomucinosis: a critical review. Ann Surg Oncol 1999;6:797–801.

    Article  PubMed  CAS  Google Scholar 

  19. Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003;138:26–33.

    Article  PubMed  CAS  Google Scholar 

  20. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000;66:561–568.

    PubMed  CAS  Google Scholar 

  21. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124–132.

    Article  PubMed  CAS  Google Scholar 

  22. Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001;92:71–76.

    Article  PubMed  CAS  Google Scholar 

  23. Zoetmulder FAN, Verwaal V, Ruth S. Hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C significantly improves survival in patients with peritoneal carcinomatosis of colorectal origin. ASCO Prog Proc 2002;21:147a.

    Google Scholar 

  24. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187–193.

    PubMed  CAS  Google Scholar 

  25. Loggie BW, Fleming R. Complications of heated intraperitoneal chemotherapy and strategies for prevention. In: Peritoneal Carcinomatosis: Principles Of Management. Boston: Kluwer Academic Publishers, 1996:222–33.

    Google Scholar 

  26. Berkery R, Cleri L, Skarin A. Chemotherapeutic agents. In: Oncology Pocket Guide To Chemotherapy. Philadelphia: SmithKline Beecham, 1997:177–80.

    Google Scholar 

  27. Sayage AC, Gilly FN, Carry PY, et al. Intraoperative chemohyperthermia in the management of digestive cancers. A general review of literature. Oncology 1993;50:333–337.

    Article  Google Scholar 

  28. Fujimoto S, Shrestha RD, Kokubun M, et al. Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer. Cancer 1989;64:154–160.

    Article  PubMed  CAS  Google Scholar 

  29. Fleming R, Loggie BW, Russell GB, Rice MA. Systemic exposure of MMC during intraperitoneal administration is correlated with hematologic toxicity and survival in patients with peritoneal carcinomatosis. Proc Am Assoc Cancer Res 1998;39:599.

    Google Scholar 

  30. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590–2611.

    PubMed  CAS  Google Scholar 

  31. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?. J Clin Oncol 1998;16:2297–2298.

    PubMed  CAS  Google Scholar 

  32. Baker SD, Verweij J, Rowinsky EK, et al. Role of body-surface area in dosing of investigational anticancer agents in adults: 1991–2001. J Natl Cancer Inst 2002;94:1883–1888.

    PubMed  CAS  Google Scholar 

  33. Fumagalli U, Trabucchi E, Soligo M, et al. Effects of intraperitoneal chemotherapy on anastomotic healing in the rat. J Surg Res 1991;50:82–87.

    Article  PubMed  CAS  Google Scholar 

  34. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001;27:65–73.

    Article  PubMed  CAS  Google Scholar 

  35. McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003;10:155–162.

    Article  PubMed  Google Scholar 

  36. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–914.

    Article  PubMed  CAS  Google Scholar 

  37. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–2947.

    PubMed  CAS  Google Scholar 

  38. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136–147.

    PubMed  CAS  Google Scholar 

  39. Fleming RA, Drees J, Loggie BW, et al. Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C. Pharmacogenetics 2002;12:31–37.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wake Forest University Baptist Medical Center, Omaha, Nebraska

    Perry Shen MD, Jason Hawksworth MD, James Lovato PhD, Kim R. Geisinger MD & Edward A. Levine MD

  2. Kucera Pharmaceutical Company, Omaha, Nebraska

    Ronald A. Fleming PharmD

  3. Winston-Salem, NC; and Creighton University Cancer Center, Omaha, Nebraska

    Brian W. Loggie MD

  4. Surgical Oncology Service, Wake Forest University Medical Center, Medical Center Blvd., Winston-Salem, NC, 27157

    Perry Shen MD

Authors
  1. Perry Shen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jason Hawksworth MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Lovato PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brian W. Loggie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kim R. Geisinger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ronald A. Fleming PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Edward A. Levine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Perry Shen MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shen, P., Hawksworth, J., Lovato, J. et al. Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C for Peritoneal Carcinomatosis from Nonappendiceal Colorectal Carcinoma. Ann Surg Oncol 11, 178–186 (2004). https://doi.org/10.1245/ASO.2004.05.009

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2004.05.009

Key Words

Search

Navigation